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Objective: Mice lacking the bHLH transcription factor (TF) Neurog3 do not form pancreatic islet cells, including insulin-secreting beta cells, the
absence of which leads to diabetes. In humans, homozygous mutations of NEUROG3 manifest with neonatal or childhood diabetes. Despite this
critical role in islet cell development, the precise function of and downstream genetic programs regulated directly by NEUROG3 remain elusive.
Therefore, we mapped genome-wide NEUROG3 occupancy in human induced pluripotent stem cell (hiPSC)ederived endocrine progenitors and
determined NEUROG3 dependency of associated genes to uncover direct targets.
Methods: We generated a novel hiPSC line (NEUROG3-HA-P2A-Venus) where NEUROG3 is HA-tagged and fused to a self-cleaving fluorescent
VENUS reporter. We used the CUT&RUN technique to map NEUROG3 occupancy and epigenetic marks in pancreatic endocrine progenitors (PEP)
that were differentiated from this hiPSC line. We integrated NEUROG3 occupancy data with chromatin status and gene expression in PEPs as well
as their NEUROG3-dependence. In addition, we investigated whether NEUROG3 binds type 2 diabetes mellitus (T2DM)eassociated variants at the
PEP stage.
Results: CUT&RUN revealed a total of 863 NEUROG3 binding sites assigned to 1263 unique genes. NEUROG3 occupancy was found at promoters
as well as at distant cis-regulatory elements that frequently overlapped within PEP active enhancers. De novo motif analyses defined a NEUROG3
consensus binding motif and suggested potential co-regulation of NEUROG3 target genes by FOXA or RFX transcription factors. We found that
22% of the genes downregulated in NEUROG3/ PEPs, and 10% of genes enriched in NEUROG3-Venus positive endocrine cells were bound by
NEUROG3 and thus likely to be directly regulated. NEUROG3 binds to 138 transcription factor genes, some with important roles in islet cell
development or function, such as NEUROD1, PAX4, NKX2-2, SOX4, MLXIPL, LMX1B, RFX3, and NEUROG3 itself, and many others with unknown
islet function. Unexpectedly, we uncovered that NEUROG3 targets genes critical for insulin secretion in beta cells (e.g., GCK, ABCC8/KCNJ11,
CACNA1A, CHGA, SCG2, SLC30A8, and PCSK1). Thus, analysis of NEUROG3 occupancy suggests that the transient expression of NEUROG3 not
only promotes islet destiny in uncommitted pancreatic progenitors, but could also initiate endocrine programs essential for beta cell function.
Lastly, we identified eight T2DM risk SNPs within NEUROG3-bound regions.
Conclusion: Mapping NEUROG3 genome occupancy in PEPs uncovered unexpectedly broad, direct control of the endocrine genes, raising novel
hypotheses on how this master regulator controls islet and beta cell differentiation.
 2021 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Diabetes results from either autoimmune destruction of beta cells
(Type 1 diabetes) or defective insulin secretion combined with pe-
ripheral tissue resistance of insulin action (Type 2 diabetes). These
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Original Articlein genes controlling beta cell development, function, or both, including
genes encoding essential transcription factors such as PTF1A, PDX1,
HNF1B, NEUROG3, RFX6, and NEUROD1 [1].
The bHLH transcription factor NEUROG3 is the key regulator of the
endocrine cell-fate decision in the embryonic pancreas. In the mouse, all
pancreatic islet cells derive from Neurog3-expressing pancreatic
endocrine progenitors (PEP) and depend on Neurog3 [2,3]. Neurog3-
deficient newborn mice die within a few days; they are diabetic, as they
lack insulin-secreting beta cells as well as all other islet cells [3]. In
humans, homozygous or compound heterozygous mutations in NEU-
ROG3 have been identified in patients who develop diabetes [4e7]. The
pathology declares at various ages, from neonatal to childhood, likely
reflecting differences in how severely NEUROG3 function is compro-
mised. Notably, patients also developed rare forms of congenital mal-
absorptive diarrhea due to a lack of intestinal endocrine cells, which do
not develop in the absence of NEUROG3 [4,8]. Moreover, endocrine cell
development has been found to require NEUROG3, proven using
pancreatic differentiation of human pluripotent stem cells as a model
[9,10].
Despite NEUROG3’s key function in endocrine commitment, the direct
genetic program implemented by NEUROG3 is largely unknown in both
mice and humans. Genome-wide approaches have been performed to
identify Neurog3-regulated genes in the mouse embryonic pancreas
[11]. However, in the absence of Neurog3, the whole islet lineage is lost;
thus, a comparison between transcriptomes of Neurog3-deficient and
control embryos revealed the entire islet transcriptome, from endocrine
progenitors to mature hormone-expressing cells, and not only Neurog3-
regulated genes. Direct Neurog3 target candidate genes such as Neu-
roD, Nkx2-2, Insm1, Pax4, Neurog3, and Cdkn1a have been charac-
terized previously using in vitro EMSA, Chromatin Immunoprecipitation
(ChIP), and transactivation assays [12e16]. Using EMSAs and ChIP-
qPCR, direct binding of NEUROG3 to NKX2-2 and NEUROG3 regulatory
regions in hES-derived pancreatic precursors were recently reported
[17]. Nevertheless, genome-wide analysis to identify the entire panel of
NEUROG3-bound regions has not been performed yet. The lack of
sensitivity of the ChIP-Seq technique combined with the scarcity of
NEUROG3-expressing endocrine progenitors has hampered this type of
study.
Here, we generated a novel hiPSC cell line where endocrine progenitor
cells can be purified and NEUROG3 is epitope-tagged. We used the
cleavage under targets and release using nuclease (CUT&RUN) tech-
nique, which allows transcription factor profiling from a low cell
number [18e20] to identify NEUROG3-bound regions across the
genome in hiPSC-derived pancreatic cells. We confirmed previously
known NEUROG3 targets, validating the experimental approach.
Importantly, we identified many unreported NEUROG3 bound genes.
Comparison with transcriptome data identified NEUROG3-bound genes
enriched in human hiPSC-derived PEPs and regulated by NEUROG3.
Our study has uncovered an unexpectedly large panel of potential
direct NEUROG3 targets, offering a novel view on how NEUROG3
controls endocrinogenesis.
2. MATERIALS AND METHODS
2.1. Culturing of hiPSC lines
Wild type SB AD3.1 [21] and NEUROG3-HA-P2A-Venus lines were
maintained as undifferentiated hiPSC in mTeSR1 medium (Stem Cell
Technology) on 1:30 diluted Matrigel- (hESC grade, Corning) coated
tissue culture surfaces, with daily medium change. Cells were seeded
at 1.5e4  10e5 in a Matrigel-coated p35 plate containing 5 mM2 MOLECULAR METABOLISM 53 (2021) 101313  2021 The Authors. Published by Elsevier GmbH. TY27632 (Stem Cell Technologies) (mTeSRþY) and split every 3 or 4
days with TrypLE Select (Fisher).
2.2. Generation of the NEUROG3-HA-P2A-Venus line
The SB AD3.1 line [21] was co-transfected with a pX458-plasmid
(Addgene) expressing the sg1 guide RNA (Suppl. Table 1) and the
Cas9 fused to GFP, as well as the targeting vector pBSII-KS-
hNEUROG3-3HA-2A-3NLS-Venus-pA (Suppl. Figure 1), both gener-
ated in the laboratory. Nucleofection was performed according to the
manufacturer instructions (Amaxa), with 8  10e5 SB AD3.1 cells
mixed with 2.5 mg of each plasmid DNA, and cells were seeded on a
p35 containing mTeSR1þY. The following day, cells were harvested
with TrypLE Select (Invitrogen), resuspended in PBS containing 2%
FCS, 10 mM Y27632, and 1% Penicillin/Streptomycin, sorted according
to expression of GFP, and seeded in mTeSR1þY. After 12 days, clones
were picked by scratching and expanded for banking while genotyping.
2.3. Genotyping
DNAwas extracted from collected cells using the Nucleospin Tissue XS kit
(Macherey-Nagel) according to the manufacturer instructions and gen-
otyped by nested PCR using primers described in Suppl. Figure 1 and
Suppl. Table 1. PCR products were purified using the Nucleospin Gel
and PCR clean-up kit (Macherey-Nagel) and sequencedwith appropriated
primers (Suppl. Table 1) at Eurofins Genomics (Ebergberg, Germany).
2.4. Differentiation of hiPSC cells to pancreatic endocrine
progenitors
Cells were differentiated according to the protocol of Petersen et al.
(2017) [21]. At 80e90% confluency, cells were harvested with TrypLE
Select and seeded at 3  10e5 cells/cm2 on Growth Factor Reduced
Matrigel-coated 24-well or 6-well plates (CellBind Corning) in
mTESRþY. Differentiation was initiated 24 h after seeding. Cells were
first rinsed with 1 PBS, then exposed daily to freshly prepared dif-
ferentiation medium (Suppl. Table 1).
2.5. Flow cytometry analyses
Cells were harvested with TrypLE Select as described above, quenched
with 3 volumes of MCDB131-3 medium containing 5 mM Y27632
(M3Y), washed once with PBS, and fixed with 4% formaldehyde in PBS
for 20 min. After 2 washes with PBS, cells were permeabilized 30 min
with PBS, Triton 0.2%, and 5% Donkey serum (permeabilization
buffer), then incubated overnight at þ4 C with primary antibodies
(Suppl. Table 1) diluted in permeabilization buffer. After 2 washes with
PBS-Triton 0.1% and 0.2% BSA (PBSTB), cells were incubated for 1e
2 h at RT with fluorophore-conjugated secondary antibodies
(Suppl. Table 1) diluted in permeabilization buffer. After 2 washes with
PBSTB, cells were resuspended at 1 M/mL in PBS, 1% BSA, filtered on
85 mm nylon mesh, and analyzed on a BD Fortessa LSR II Cell analyser
(BD Bioscience).
2.6. Immunofluorescence imaging
Cells were washed twice with PBS, fixed with 4% formaldehyde in PBS
for 20 min, permeabilized for 30 min with PBS-Triton 0.5%, and
blocked for 30 min in PBSTB. Cells were incubated with primary an-
tibodies (Suppl. Table 1) diluted in PBSTB overnight at 4 C, washed
3 in PBS-Triton 0.1%, and incubated for 1e2 h at RT with
fluorophore-conjugated secondary antibodies (Suppl. Table 1) diluted
in PBSTB. Cells were washed twice in PBSTB and nuclei were stained
with Dapi 50 ng/mL in PBST. Image acquisition was done on the Leica
DMIRE2 inverted fluorescence microscope.his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.7. Flow cytometry sorting of Venusþ cells
Cells were harvested with TrypLE Select at day 13 of differentiation,
quenched with 3 volumes of M3Y, centrifuged 4 min at 200 g,
resuspended at 5 M/mL in M3Y, and sorted using a FACSAria Fusion
cell sorter (BD) in M3Y at þ4 C. Venusþ cells were collected and
either used immediately or cryoconserved in Cryostor10 (Stem Cell
Technologies) at 80 C.
2.8. RNA-seq libraries and data processing
Cells differentiated to day 13 in 24-well plates (N ¼ 4, from 2 inde-
pendent differentiations) were sorted according to Venus expression,
and RNAs were prepared with the RNeasy Micro kit (Qiagen). Libraries
were prepared using SMART-SeqX v4 UltraX Low Input RNA Kit for
Sequencing (Takara Bio Europe) and the Nextera XT DNA Library
Preparation Kit (Illumina, San Diego, USA), purified with SPRIselect
beads (Beckman-Coulter, Villepinte, France), and sequenced on an
Illumina HiSeq 4000 (single-end 50 bp reads). Reads were mapped
onto the hg38 human genome using STAR version 2.7.5a [22].
Quantification of gene expression was performed using HTSeq version
0.6.1 [23] and gene annotations from Ensembl release 98. Normali-
zation of read counts and differential expression analysis between
Venus-negative and Venus-positive samples were performed using the
method implemented in the DESeq2 Bioconductor library version
1.16.1 [24].
Differential expression analyses for comparing Venus-positive and
Venus-negative samples as well as the NEUROG3/ hESC line
differentiated to day 13 and its wild-type counterpart [25] were per-
formed using a negative binomial GLM fit and Wald significance test
implemented in the Bioconductor package DESeq2 version 1.16.1 [26].
The variables considered for the GLM model were condition (for the
Venus-labeled cells) and batch and condition (in the NEUROG3/
comparison), in which batch corresponds to two differentiations (2
controls and 2 mutants per differentiation). Differentially expressed
genes were defined as those having a Benjamini-Hochbergeadjusted
Wald test with P < 0.05, and a log2 fold change greater than 1, in the
case of Venus-labeled cells.
2.9. CUT&RUN
We followed the protocol of Hainer and Fazzio (2019) [27] with minor
modifications. Cells (75,000 for anti NEUROG3, HA and CTRL donkey
anti sheep (DAsh) antibodies, 18,000 for H3K4me3 antibody, and
15,000 for H3K27me3 and Rabbit anti-Mouse control antibodies, one
sample per antibody) were washed once with 1 mL cold PBS and
resuspended in nuclear extraction buffer (NE, 20 mM HEPES-KOH, pH
7.9, 10 mM KCl, 0.5 mM Spermidine, 0.1% Triton X-100, 20% glyc-
erol, freshly added protease inhibitors). After 3 min spinning at 4 C at
600g, cells were resuspended in 600 mL NE buffer. Concanavalin A
beads (Polysciences, 25 mL bead slurry/sample) were washed twice
with ice-cold Binding buffer (20 mM HEPES-KOH, pH 7.9, 10 mM KCl,
1 mM CaCl2, 1 mM MnCl2) and resuspended in 300 mL Binding buffer.
Nuclei were added to beads with gentle vortexing and incubated for
10 min at 4 C with gentle rocking. Bead-bound nuclei were blocked
with 1 mL cold Blocking buffer (20 mM HEPES, pH 7.5, 150 mM NaCl,
0.5 mM Spermidine, 0.1% BSA, 2 mM EDTA, freshly added protease
inhibitors) by gentle pipetting, incubated 5 min at RT, washed in 1 mL
cold Wash buffer (WB, 20 mM HEPES, pH 7.5, 150 mM NaCl, 0.5 mM
Spermidine, 0.1% BSA, freshly added protease inhibitors), and
resuspended in 250 mL cold WB. 250 mL of primary antibody
(Suppl. Table 1) diluted 1:100 in cold WB were added with gentle
vortexing, and samples were incubated overnight with gentle rocking
at 4 C. Samples were washed twice in 1 mL cold WB andMOLECULAR METABOLISM 53 (2021) 101313  2021 The Authors. Published by Elsevier GmbH. This is an open a
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secondary antibody (Donkey anti-Sheep IgG, 1:200) was performed for
1 h at 4 C in WB under gentle rocking. After 2 washes with 1 mL WB
and resuspension in 250 ml WB, 200 mL of pAeMN (diluted at 1.4 ng/
mL in cold WB) was added with gentle vortexing, and samples were
incubated with rotation at 4 C for 1 h. The protein Aemicrococcal
nuclease recombinant protein (pAeMN) was produced in-house ac-
cording to the protocol described by Schmid et al. [28] and using the
pK19pAeMN plasmid, obtained from Ulrich Laemmli (RRID:Addg-
ene_86973; http://n2t.net/addgene:86973). Samples were washed
twice in 1 mL cold WB and resuspended in 150 mL cold WB. 3 mL of
100 mM CaCl2 were added upon gentle vortexing to activate the MN.
After 30 min of digestion, reactions were stopped by addition of 150 mL
2XSTOP buffer (200 mM NaCl, 20 mM EDTA, 4 mM EGTA, 50 mg/mL
RNaseA, 40 mg/mL glycogen) and DNA fragments were released by
passive diffusion during incubation at 37 C for 20 min. After centri-
fugation for 5 min at 16,000g at þ4 C to pellet cells and beads, 3 mL
10% SDS and 2.5 mL Proteinase K 20 mg/mL were added to the
supernatants, and samples were incubated 10 min at 70 C. DNA
purification was done with phenol/chloroform/isoamyl alcohol extrac-
tion followed by chloroform extraction using MaxTract tubes (Qiagen).
DNA was precipitated with ethanol after addition of 20 mg glycogene
and resuspended in 36.5 mL 0.1XTE.
2.10. High throughput sequencing of CUT&RUN samples
Illumina sequencing libraries were prepared at the Genomeast facility
(IGBMC, Illkirch). CUT&RUN samples were purified using Agencourt
SPRIselect beads (Beckman-Coulter). Libraries were prepared from
10 ng of double-stranded purified DNA using the MicroPlex Library
Preparation kit v2 (Diagenode) following the manufacturer’s protocol
with some modifications. Illumina-compatible indexes were added
through a PCR amplification (3 min at 72 C, 2 min at 85 C, 2 min at
98 C; [20 s at 98 C, 10 s at 60 C]  13 cycles). Amplified libraries
were purified and size-selected using Agencourt SPRIselect beads
(Beckman Coulter) by applying the following ratio: volume of beads/
volume of libraries ¼ 1.4/1. The libraries were sequenced on Hiseq




Image analysis and base calling were performed using RTA 2.7.3 and
bcl2fastq 2.17.1.14. Reads were trimmed using cutadapt v1.9.1 with
option: -a AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC -A
AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTA -m 5 -e 0.1. Paired-
end reads were mapped to Homo Sapiens genome (assembly hg38)
using Bowtie2 (release 2.3.4.3, parameter: -N 1 -X 1000). Reads
overlapping with ENCODE hg38 blacklisted region V2 were removed
using Bedtools. Reads were size selected to <120 bp and >150 bp,
as it has been reported that small reads define more precisely TF
binding sites, whereas larger reads (>150 bp) result from sites
occupied by nucleosomes [18,19]. Bigwig tracks were generated using
bamCoverage from deepTools for 120 bp and 150 bp fragments
separately. Tracks were normalized with RPKM method. The bin size
was 20. 120 bp fragments were used for samples obtained with
anti-NEUROG3 (VLSR28), HA (VLSR27) and the control Donkey anti-
Sheep (DAsh, thereafter named CTRL, VLSR29) antibodies and
150 bp fragments for samples obtained with anti-H3K4me3
(VLSR32), anti-H3K27me3 (VLSR44), and the Rabbit anti-Mouse
control (RAM, VLSR41) antibodies. Bigwig tracks (reads 120 bpccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 3
Original Articlelong for NEUROG3, HA, and CTRL samples and 150 pb for histone
marks) were displayed on the reference genome hg38 using the UCSC
genome browser. For simplicity, only the DAsh CTRL is illustrated
throughout the manuscript. Heatmaps and K-means clustering was
done using seqMINER v1.3.3g [29]. To compare with previously
published data obtained from human in vitro-derived pancreatic
endocrine progenitors [30], multipotent progenitors [31], and adult
islets [32], we converted coordinates of bed and bigwig files to hg19
coordinates using the UCSC Liftover and bigwigLiftOver tools (https://
github.com/milospjanic/bigWigLiftOver), respectively. Genomic tracks
were visualized using http://meltonlab.rc.fas.harvard.edu/data/UCSC/
SCbetaCellDiff_ATAC_H3K4me1_H3K27ac_WGBS_tracks.txt.
2.11.2. Peak calling
Peak calling was performed with the Sparse Enrichment Analysis for
CUT&RUN SEACRv1.3 tool [33] (https://seacr.fredhutch.org), using the
norm and stringent modes on the 120 bp size selected reads and
VLSR29 (DAsh CTRL) as a control for VLSR27 (HA) and VLSR28
(NEUROG3) datasets. To identify overlapping genomic regions, peak
coordinates were intersected using the BEDtools 2.22.0 command
intersect interval files (http://use.galaxeast.fr).
2.11.3. Association of peaks with genomic features and genes
Genomic annotation was first performed using the HOMER v3.4 [34]
annotatePeaks.pl script with the default settings (promoters-tran-
scription start site (TSS) from 1 kb to þ100 bp to the TSS and
transcription termination sites (TTS) from 100 bp to þ1 kb of the
TTS). GREAT 4.0.4 [35] was used to assign NEUROG3/HA peaks to
their nearest coding gene(s) using basal settings (each gene is
assigned a basal regulatory domain of 5 kb upstream and 1 kb
downstream of its TSS. The gene regulatory domain is extended in
both directions to the nearest gene’s basal domain, but no more
than 1000 kb extension in one direction. Each peak is associated
with all genes with whose regulatory domain it overlaps). The
NEUROG3 peaks or the distal peaks defined by GREAT (>5 kb from
TSS) were intersected with enhancers regions of hESC-derived
endocrine progenitors (EN) lifted over to the hg38 genome ([30],
GSE139816).
2.11.4. Motifs identification and analyses
De novo motif discovery was performed using the HOMER v3.4 [34]
findMotifsGenome.pl script with default settings (200-bp windows
centered on peak summits, motif lengths set to 8, 10, and 12 bp,
hypergeometric scoring). For enrichment of known motifs, the entire
peak sequence was considered using the -size given option. For the 6
most significant de novo motifs identified, known best match motifs
were associated if their Homer score was >0.85. Known co-
occurring motifs were manually curated to exclude redundant bHLH
motifs. Co-occurrence of the de novoeidentified NEUROG3 motif and
known RFX6 or FOXA2 motifs was done on the entire peak sequences
using the HOMER script annotatePeaks.pl with -size given and
-m <motifn.motif> options.
2.11.5. Functional annotations
Gene functional annotation and clustering was carried out with DAVID
v6.8 (https://david.ncifcrf.gov/home.jsp, [36]), using GO Biological
Process, GO Cellular Component, and KEGG Pathways. Selected terms
significantly enriched and sorted by Log(P-value) are displayed. To
identify NEUROG3 transcription factor target genes, the peaks-
assigned gene names were intersected by Venny 2.1.0 (https://
bioinfogp.cnb.csic.es/tools/venny/) with a list of 1734 TF combining4 MOLECULAR METABOLISM 53 (2021) 101313  2021 The Authors. Published by Elsevier GmbH. Tthe 1639 human TF identified by Lambert et al. [37] with the 1496
human TF taken from the human protein atlas (https://www.
proteinatlas.org).
2.11.6. Overlap between bound genes and differentially expressed
genes
The lists of the 312 genes downregulated in NEUROG3/ hESC cells
and 3030 genes enriched in NEUROG3-HA-P2A-Venus hiPSC cells,
differentiated to PEP, were intersected with the list of NEUROG3-bound
genes by Venny 2.1.0. Expression of genes of interest in the human
fetal pancreas and during in vitro differentiation of human embryonic
stem cells into pancreatic endocrine cells was examined using https://
descartes.brotmanbaty.org [38] and http://hiview.case.edu/public/
BetaCellHub/differentiation.php [39], respectively.
2.11.7. Overlap between NEUROG3 bound sites and cis-regulatory
elements
NEUROG3-bound regions were intersected using Bedtools 2.29.2 with:
(1) human in vitroederived multipotent pancreatic progenitor en-
hancers (MPC Enhancers), cis-regulatory modules (MPC CRM), and
transcription factor binding sites (ChIP-seq datasets) [31]; (2) in vitroe
derived pancreatic endocrine progenitor enhancers (EN_enhancers)
[30]; (3) adult islet regulatory elements (islet regulome) [32]; and (4)
the 23,144 genetic variants associated with T2D and glycemic traits
(T2D-FG) on 109 loci, compiled by Miguel-Escalada et al. [32]. When
necessary, coordinates of bed files were converted to hg19 or hg38
coordinates using the UCSC Liftover tool. Enrichment P-values of
overlapping regions were calculated using Bedtools v2.29.2 Fish-
erBedtool or, when indicated, using CEAS (one-sided binomial test)
[40].
2.11.8. Data availability
Raw data have been deposited in the GEO database under accession
code GSE179264 for CUT&RUN data and RNA-seq data on NEUROG3-
HA-P2A-Venusþ and Venus PEP cells. hESC-derived NEUROG3/
[25] RNA-seq data are from E-MTAB-7185. hESC-derived endocrine
progenitors (EN) data (enhancers, H3K27ac ChIP-seq and RNA-seq,
Ref [30]) are from GSE139817.
2.12. Luciferase assays
Sequences encompassing NEUROG3-bound regions determined by
CUT&RUN and assigned to MLXIPL, ETS2, and ISX genes were PCR
amplified using primers listed in Suppl. Table 1 and cloned into
pGL4.23 vector. Luciferase activity was assessed in HEK293T cells by
co-transfection of reporter constructs with pcDNA3-NEUROG3-3HA-
P2A-3NLS-Venus (þNEUROG3) or pcDNA3 empty vector (no NEU-
ROG3) and Renilla luciferase expressing plasmid for normalization.
3. RESULTS AND DISCUSSION
3.1. Identification of NEUROG3 targets in hiPSC-derived endocrine
progenitors
To unveil the endocrinogenic program implemented by NEUROG3, we
mapped NEUROG3 occupancy across the genome during directed
differentiation of hiPSC into beta cells. We first generated an hiPSC line
where NEUROG3 was tagged with 3 HA epitopes and fused to a
cleavable nuclear VENUS fluorescent reporter (NEUROG3-HA-P2A-
Venus) (Figure 1A and Suppl. Figure 1). Using the protocol described by
Petersen et al. (2017) [21] and adapted from Rezania et al. (2014) [41],
we differentiated the NEUROG3-HA-P2A-VENUS hiPS cells along the
pancreatic and islet lineage until the pancreatic endocrine progenitorhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1: Characterization of the genome-wide binding sites of NEUROG3 in human hiPSC-derived pancreatic endocrine progenitors. (A) Overview of the study: a 5-stage
protocol was used to differentiate hiPSC to pancreatic endocrine progenitors using the sequential supplementation of factors indicated. At day 13, Venusþ cells were sorted and
used in a CUT&RUN experiment. Inset: schematic representation of the NEUROG3-3HA-P2A-3NLS-Venus allele. (B) Venn diagram showing the number and overlap of peaks
identified by CUT&RUN with an anti-NEUROG3 or an anti-HA antibody. (C) Genomic distribution (number and % of peaks) of the 863-high confidence NEUROG3 binding sites. (D)
Distance of NEUROG3 peaks to their gene(s)-associated TSS. (E) Overlap between NEUROG3 distal binding sites (>5 kb from TSS) and enhancers regions of hiPSC-derived
endocrine progenitors (EN), as defined by Alvarez-Dominguez et al. [30], P ¼ 4.9e-324. (F) Normalized read density surrounding NEUROG3 peak summit 5 Kb for
H3K4me3 and H3K27me3 CUT&RUN datasets. (G) Genome browser tracks showing NEUROG3, HA, H3K4me3, H3K27me3, and the CTRL (Donkey anti-Sheep antibody) CUT&RUN
data at the NEUROD1, NKX2-2, NEUROG3, PAX4, and INSM1/RALGAPA2 loci. Identified NEUROG3 peaks are highlighted in light blue. Peaks matching previously reported NEUROG3
binding sites are indicated by blue arrowheads, newly discovered peaks by purple arrowheads, and reported sites not confirmed here by gray arrowheads [12,13,15e17].(PEP) stage (day 13) (Figure 1A). We verified that NEUROG3-positive
cells do indeed co-express HA and Venus by immunofluorescence
(Suppl. Figure 2AeB). Accordingly, FACS analyses showed a corre-
lation between HA and Venus expression (Suppl. Figure 2C). All theMOLECULAR METABOLISM 53 (2021) 101313  2021 The Authors. Published by Elsevier GmbH. This is an open a
www.molecularmetabolism.comVenusþ cells expressed PDX1 (Suppl. Figure 2A, C), as expected and
previously shown with a NEUROG3-eGFP hiPSC line [21]. To map
NEUROG3-bound regions, we used the CUT&RUN technique, an
alternative to ChIP-seq for low input cell numbers [18,19]. Thisccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 5
Original Articletechnique is based on the recruitment of micrococcal nuclease, fused
to protein A (pAeMNase), to antibody-bound sites within the genome
in intact nuclei (Figure 1A). The subsequently cleaved fragments are
recovered and sequenced. Endocrine progenitors were purified at day
13 (d13) of differentiation (Suppl. Figure 2D), and CUT&RUN experi-
ments were performed on Venusþ cells using anti-NEUROG3 and anti-
HA antibodies. We also profiled active (H3K4me3) and repressive
(H3K27me3) histone marks to map chromatin states.
We identified 1873 and 1428 peaks using NEUROG3 and HA antibodies,
respectively (Figure 1B). To enhance the stringency of NEUROG3-bound
regions, we intersected both datasets, defining NEUROG3 occupancy at
863 common sites (Figure 1B and Suppl. Table 2). These high-
confidence NEUROG3 binding sites were found at promoters (35%),
introns (30%), and intergenic regions (31%) (Figure 1C) and were
assigned by GREAT to 1263 unique genes, with 573 peaks (66%)
assigned to 2 or more genes (Suppl. Table 3). NEUROG3 binding to
distal regions (located >5 kb from the TSS of their associated gene)
was observed for 65% of sites (557 peaks for 1042 genes) (Figure 1D).
Remarkably, 90.8% (506 peaks, P ¼ 4.9e-324) of these distal NEU-
ROG3-bound regions were located within enhancer regions of hESC-
derived endocrine progenitors (EN), as defined through their H3K27
acetylation by Alvarez-Dominguez et al. (2019) [30] (Figure 1E). In
agreement, we found that H3K4me3 active histone marks were
enriched at the NEUROG3 peaks compared to the H3K27me3 repressive
marks (Figure 1F), indicating NEUROG3 binding at active promoters and
enhancers. Taken together, we uncovered the NEUROG3 cistrome in
PEPs, suggesting that NEUROG3 activates gene transcription by binding
both proximal and distal cis-regulatory elements.
3.2. CUT&RUN detects previously identified and novel binding sites
in known NEUROG3 targets
To validate the CUT&RUN approach for identifying NEUROG3-bound
regions in PEPs, we first examined previously characterized direct
targets. As expected, we identified peaks in NEUROD1, NKX2-2, PAX4,
INSM1, and NEUROG3 [12,13,15e17], some of them at sites already
mapped by ChIP-qPCR, EMSA, or luciferase assays (Figure 1G). Inter-
estingly, we identified two unreported NEUROG3 binding sites upstream
of the NKX2-2 gene and upstream of NEUROG3 TSS (purple arrowheads
in Figure 1G). The sites identified for NEUROG3 were distinct from the
one reported previously by ChIP-qPCR [17], but overlapped with the
conserved Neurog3 enhancer region described in the mouse [42],
supporting the idea that NEUROG3 regulates its own transcription [12].
The peak assigned to INSM1 may be distantly located (>180 kb
downstream of its TSS, within an intron of the RALGAPA2 gene), but the
region has been identified as a super-enhancer directly linked to the
INSM1 gene using promoter capture HiC studies performed in adult
pancreatic islets [32] (Figure 1G and Suppl. Figure 3), suggesting a role
in the regulation of INSM1 expression. Of note, we found no binding site
for the CDKN1A gene, shown in the mouse to be directly regulated by
NEUROG3 and promote cell cycle exit in PEP [14]. It is possible that the
NEUROG3 target NEUROD1 serves as an intermediate, since NEUROD1
was shown to similarly inhibit cell proliferation by directly regulating
Cdkn1a transcription [43]. Altogether, these data validate use of the
CUT&RUN technique to unravel NEUROG3 binding sites genome-wide
and suggest that the expected NEUROG3-driven endocrinogenic pro-
grams are activated in hiPSC-derived PEP.
3.3. Consensus NEUROG3 binding motif and co-binding of
transcription factors
To determine the motifs enriched in the NEUROG3 binding regions, we
performed a de novo motifs analysis [34] that revealed a strong6 MOLECULAR METABOLISM 53 (2021) 101313  2021 The Authors. Published by Elsevier GmbH. Tenrichment for the RCCATCTGBY E-box type motif (CANNTG) recog-
nized by bHLH transcription factors (Figure 2A). The NEUROG3
recognition motif is similar to NEUROD1 and NEUROG2 binding motifs,
in agreement with the strong homology of the bHLH DNA binding
domains between NEUROD and NEUROG families. Several additional
motifs were also significantly enriched in NEUROG3 binding regions,
such as the motif recognized by NFY, FOX, SP/KLF, RFX, and PBX TFs
(Figure 2AeC and Suppl. Figure 4). Some TFs of these families have
been reported to regulate pancreas development and islet cell differ-
entiation, such as Pbx1 [44], Rfx3, and Rfx6 [45,46]. Interestingly, the
binding of the general NFY factors was reported biased towards reg-
ulatory elements with enhancer activity [47]. In agreement with our
findings, KLF, FOXA1/A2, RFX, and MEIS1 (a PBX1 related homeobox
gene) TFs were recently predicted to bind to PEP Super Enhancers in a
model of Core transcriptional regulatory circuits (CRCs) in the human
islet lineage [30]. Of particular interest are FOX and RFX motifs in
NEUROG3-bound regions (Figure 2C and Suppl. Table 4). Indeed,
FOXA1 and FOXA2 act as pioneer factors, facilitating chromatin access
to other TFs at multiple stages during pancreas development [48]. We
found that 28.27% of the NEUROG3 peaks harbor a FOXA2 motif
(Figure 2B). Studies of in vitroederived human multipotent progenitor
cells (MPC) showed that FOXA2, ONECUT1, GATA6, HNF1b, PDX1, and
TEAD1 define cis-regulatory modules (CRM) as active enhancers
bound by at least 2 of these TFs, which are essential for early pancreas
development [31]. Whereas all 6 TF binding sites showed a significant
enrichment at NEUROG3 binding sites relative to their genomic fre-
quency, FOXA2 was the most significantly enriched, with 189 (21.9%;
P ¼ 1.4e-207) of NEUROG3 binding sites bound by FOXA2 in MPCs
(Figure 2D) [31]. Furthermore, 41 NEUROG3 peaks (4.7%; P ¼ 1.93e-
48) overlapped with a CRM, of which 36 were co-bound by FOXA2
(Figure 2D). The pioneer activity of FOXA2, also described during hu-
man in vitro pancreatic progenitor differentiation [49], could be
required for the subsequent gene activation mediated by NEUROG3 at
primed enhancers. The fact that FOXA2 regulates NEUROG3 (as shown
in mice [42]) together with our findings that NEUROG3 binds FOXA2
(Figure 2E) provides evidence towards a possible regulatory loop be-
tween these two TFs. Interestingly, we identified an RFX6 motif in
37.54% of NEUROG3 peaks (Figure 2B) and revealed the co-
occurrence of the NEUROG3 motif with the RFX6 motif in one-fifth of
the peaks, from which one-third had an additional FOXA2 motif
(Figure 2C). Several NEUROG3-bound genes were previously identified
as Rfx6 targets in a mouse beta-cell line [45] (Figure 2C and data not
shown). Altogether, FOXA2, and RFX6 may be important coregulators
of the transcription of NEUROG3 direct targets.
3.4. Integration of NEUROG3 occupancy and gene expression in the
islet lineage
Gene ontology (GO) analyses revealed that NEUROG3-bound regions
are associated with GO terms such as endocrine pancreas develop-
ment and insulin secretion, in agreement with the expected pro-
endocrine function of NEUROG3 (Figure 3A and Suppl. Table 5).
Therefore, we scrutinized NEUROG3-bound genes expressed in the
islet lineage: we reasoned that these genes should be downregulated
in NEUROG3/ cells or upregulated in NEUROG3-enriched cells. To
address this, we used RNA-seq data comparing the transcriptome of
NEUROG3/ against a wild-type hESC line, differentiated to d13 [25].
From the 319 differentially expressed genes in NEUROG3/ cells, 312
were downregulated (Suppl. Table 6), and NEUROG3 directly bound 69
(22%) of them (Figure 3BeC). We also performed RNA-seq analyses
on NEUROG3-HA-P2A-Venus hiPSC cells differentiated to d13 and
sorted for Venusþ and Venus expression. From the 3030 enrichedhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 2: TF motifs discovery in NEUROG3 binding sites. (A). De novo motif discovery ranked by P-value, reflecting motif enrichment within peak summit 100 bp. Number (#)
and % of target and background sequences harboring each motif is indicated for the 6 most significant motifs identified. Known best matching transcription factors were
associated if their HOMER score was >0.85. (B) Selection of known co-occurring motifs ranked by P-value within the entire peak sequences. The full list of the 50 most
significantly enriched motifs is shown in Suppl Figure 4. (C) Co-occurrence of NEUROG3 de novoeidentified motifs with motifs for RFX6 and/or FOXA2 on the entire peak se-
quences. Some selected GREAT assigned genes are indicated, in bold when identified as targets for Rfx6 in a mouse beta cell line [45]. (D) Regions bound by NEUROG3 at PEP
stage that are bound by FOXA2 and indicated TFs at the MPC stage. NEUROG3 cistrome was intersected with that of FOXA2, ONECUT1, TEAD1, GATA6, PDX1, and HNF1b from
in vitroederived MPC and, as a control, with that of SOX2 from hESC cells, taken from Ref. [31]. P-value of enrichment at NEUROG3 binding sites relative to genomic distribution is
calculated by CEAS. In the left panel, the number of NEUROG3-bound and NEUROG3/FOXA2-bound CRMs is indicated. (E) Genome browser tracks showing NEUROG3, HA, and the
CTRL CUT&RUN data at the FOXA2 loci. Coordinates are from hg19. The positions of NEUROG3 binding sites are highlighted in light blue (or in gray, when identified in a single
dataset). Data of RNA-seq (EN_RNA), H3K27ac ChIP-seq (EN_K27AC), and the position of enhancers (EN Enhancers) from hESC-differentiated to endocrine progenitors were taken
from Ref. [30] and http://meltonlab.rc.fas.harvard.edu/data/UCSC/SCbetaCellDiff_ATAC_H3K4me1_H3K27ac_WGBS_tracks.txt. Position of hESC-derived multipotent progenitor
cells (MPC) enhancers and cis-regulatory modules (CRM) are taken from Ref. [31]. Data from adult islets (Super-enhancers, Islet regulome, T2D/FG SNP and TAD-like regions) are
taken from Ref. [32], isletregulome.org and http://epigenomegateway.wustl.edu/.genes in NEUROG3-Venusþ cells, 295 were bound by NEUROG3,
including 63 that were downregulated in the NEUROG3/ cells
(Figure 3BeD, Suppl. Tables 7 and 8). Many of these genes encode for
TFs or proteins known to regulate islet cell differentiation and function
(see below). Thus, a total of 301 genes specifically expressed in the
endocrine lineage (out of 3063) are bound by NEUROG3, suggesting
that NEUROG3 directly regulates the expression of about 10% of islet
enriched genes. In addition, we compared the NEUROG3 cistrome with
the human pancreatic adult islet regulome [32]. We found that 782
(90.6%; P ¼ 4.9e-324) NEUROG3 binding sites matched with at least
one of the adult islet regulatory elements, with 655 (75.90%;
P ¼ 4.9e-324) localized within active enhancers or promotersMOLECULAR METABOLISM 53 (2021) 101313  2021 The Authors. Published by Elsevier GmbH. This is an open a
www.molecularmetabolism.com(Figure 3E and F). This suggests that most of the genes regulated by
NEUROG3 are still active in the adult islets, supporting the hypothesis
that the transient expression of NEUROG3 at the PEP stage is required
to initiate the endocrinogenic program, while other transcription factors
sustain the transcription of NEUROG3 targets in mature islets by
binding to the same regulatory elements.
3.5. NEUROG3 binds to a subset of islet enriched transcription
factor genes
To better understand how NEUROG3 drives islet cell differentiation, we
first examined the TF genes bound by NEUROG3. Among the 1263
NEUROG3-bound genes, 138 encode for TFs (Figure 4A andccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 7
Figure 3: Integration of NEUROG3 occupancy and islet expression of target candidates. (A) Gene ontology analysis (biological process, KEGG pathways) showing selected
significantly enriched terms (Log10[P-value]  2) related to the 1263 NEUROG3 bound genes. (B) Venn diagram illustrating the overlap of NEUROG3 bound genes and the 312
downregulated genes in NEUROG3/ hESC line differentiated to PEP stage (NEUROG3/ down; [25]) and the 3030 genes enriched in NEUROG3-HA-P2A-Venusþ compared to
Venus cells differentiated to PEP stage (NEUROG3-Venusþ enriched). (C) List of the 69 NEUROG3 target genes downregulated in NEUROG3/ PEP. In italics, the 6 bound genes
downregulated in NEUROG3/ PEP but not enriched in NEUROG3-Venusþ PEP. (D) MA-plot representing the estimated Log2 fold change as a function of the Log2 mean
expression of genes enriched in NEUROG3-Venusþ (green) or NEUROG3-Venus (red) cells. (EeF) NEUROG3 binding sites matching with one or more islets regulatory element(s)
(islet regulome; [32]). OCR, open chromatin regions, CTCF, CTCF binding sites.
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Figure 4: NEUROG3 binding to transcription factor genes. (A) NEUROG3 binds 138 genes encoding human TFs. A selection of TF genes is given. Complete list is given in Suppl
Table 9, with the list of 1734 human TFs taken from Ref. [37] and https://www.proteinatlas.org. The 24 TFs enriched in NEUROG3-Venusþ pancreatic endocrine progenitors,
among which 8 are downregulated in NEUROG3/ endocrine progenitors [25], are underlined and in bold, respectively. The 14 TFs belonging to Core Regulatory Circuits (CRCs) in
endocrine progenitors as defined by Alvarez-Dominguez et al. [30] are in red. (BeD) NEUROG3 binding to the (B) MLXIPL, (C) LMXIB, and (D) RFX3-GLIS3 loci. See Figure 2E for
legend description. In (D), RNA-seq data from primary islet beta (Beta-RNA) and alpha (Alpha-RNA) cells are taken from Ref. [30].Suppl. Table 9). Of those, 24 were enriched in NEUROG3-Venusþ hiPSC-
derived endocrine progenitors, including 8 genes also downregulated in
NEUROG3/ cells. Besides the TF genes already mentioned above
(NKX2-2, NEUROD1, NEUROG3, PAX4, INSM1, and FOXA2), we unrav-
eled several other TFs known to control islet cell development in the
mouse or human, including SOX4, RFX3, ST18 (MYT3), MLXIPL, NKX6-
1, and LMX1B (Figure 4A and data not shown), suggesting that they
could also be regulated directly by NEUROG3. For instance, NEUROG3
binds to a region in intron 1 of MLXIPL (Figure 4B) previously shown to
be bound by Rfx6 and Nkx2-2 in the mouse [45,50]. Using Luciferase
assays in HEK293T cells, we confirmed that this region effectivelyMOLECULAR METABOLISM 53 (2021) 101313  2021 The Authors. Published by Elsevier GmbH. This is an open a
www.molecularmetabolism.commediates NEUROG3 transcriptional activation (Suppl. Figure 5). Inter-
estingly, we found a NEUROG3 binding site 33 kb upstream of SOX4 TSS
and three additional peaks within the adjacent CDKAL1 locus
(Suppl. Figure 6). The latter region likely acts as a distant enhancer to
regulate SOX4 in islet cells, as suggested by promoter capture HiC data
[32], and was found to be an activated enhancer (H3K27ac enriched) at
the endocrine progenitor stage as well [30] (Suppl. Figure 6). Thus, while
Sox4 has been shown to regulate Neurog3 expression and be required
downstream of Neurog3 to regulate endocrine differentiation in the
mouse [51], SOX4 may, in turn, be a direct target of NEUROG3.
Importantly, we found that NEUROG3 binds to intron 2 of LMX1B, access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 9
Figure 5: NEUROG3 binds to transcription factor genes enriched in islet cell types. (A) Enriched expression of transcriptional regulators in islet cell types, NKX6-1 for beta
cells and IRX1, IRX2 for alpha cells, in the human fetal pancreas (taken from https://descartes.brotmanbaty.org). Expression of INS and GCG is provided to define developing beta
and alpha cells, respectively. (BeC) NEUROG3 binding to NKX6-1 (B) and IRX1-IRX2 (C) loci. See Figure 2E for legend description.
Original Articletranscription factor recently reported to be critical for generating human
islet cells downstream of NEUROG3, suggesting direct transcriptional
regulation of LMX1B by NEUROG3 (Figure 4C) [30]. Additionally, a
NEUROG3 peak within the GLIS3 coding sequence (exon 8) was
assigned to both GLIS3 and RFX3 (Figure 4D). This peak nicely overlaps
with an enhancer region at both endocrine progenitor and adult islets
stages [30,32]. In the adult islets, HiC showed that the two genes are
spatially linked [32]. Moreover, only RFX3 is highly expressed at the
endocrine progenitor stage (Figure 4D, [30]) and has recently been
documented as a human endocrine fate switch gene regulator [39].
Taken together, these data suggest a possible regulation of RFX3 by
NEUROG3 at the endocrine progenitor stage.
In a recent study, Alvarez-Dominguez et al. [30] described Core
transcriptional Regulatory Circuits (CRCs) for every stage of in vitro
beta cell differentiation, based on interconnected autoregulatory
loops between TFs. Strikingly, NEUROG3 binds 35% of the 40 TF
genes defining the endocrine progenitors CRCs: LMX1B, FOXA1,
FOXA2, FOXP1, GATA4, INSM1, KLF3, KLF13, NKX2-2, RFX3, SOX4,
SOX11, PAX4, and PBX1 (Figure 4A). Of note, since the definition of
CRCs relied on TF recognition motifs, NEUROG3, whose motif was not
yet known, could not be integrated into the endocrine progenitor10 MOLECULAR METABOLISM 53 (2021) 101313  2021 The Authors. Published by Elsevier GmbH. TCRCs [30]. Our data provide novel molecular mechanistic insights
into the role of NEUROG3 as a possible direct regulator of many TFs of
the endocrine CRCs.
We further scrutinized the TFs dataset to examine whether NEUROG3
binds to genes known to control islet cell type development and unveil
novel candidates. We focused on transcription factor genes for which
NEUROG3 binding site(s) coincided with endocrine progenitor active
enhancer regions [30] and enriched in developing alpha, beta, or delta
cells based on recent transcriptomic profiling of the human fetal
pancreas [38] (Figure 5A and Suppl. Figure 7A). An essential role of
NEUROG3 in promoting the beta cell fate is supported by its direct
regulation of Pax4 expression, a critical regulator of beta cell devel-
opment [52]. In addition to Pax4, Nkx6-1 is critical for endocrine
progenitors to acquire a beta destiny in the mouse [53]. Supporting a
possible direct regulation of NKX6-1 by NEUROG3, we found a peak
466 kb downstream of NKX6-1 TSS (Figure 5B). This region overlaps
with an endocrine progenitorespecific active enhancer region, sug-
gesting that this site may be important for NEUROG3-regulated
expression of NKX6-1 in human islet progenitors. NEUROG3 binding
sites were also associated with genes encoding TFs previously re-
ported as markers for beta cells based on their expression, but not yethis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 6: NEUROG3 binding to genes regulating glucose-dependent insulin secretion. (A) Schematic representation of insulin secretion upon glucose sensing in a beta cell.
The NEUROG3-bound genes are indicated in red. (BeH) NEUROG3 binding to genes involved in glucose-stimulated insulin secretion: (B) GCK; (C) ABCC8-KCNJ11; (D) CACNA1A; (E)
CHGA. See Figure 2E for legend description.functionally addressed in endocrine cell development, such as SMAD9
[54] and TFCP2L1 [54] (Suppl. Figure 7). For TFCP2L1, however, the
NEUROG3 binding region was not identified as an endocrine progenitor,
but as an adult islet enhancer [32] (Suppl. Figure 7B). Of note, we
additionally discovered ETS2 and ISX as potential new NEUROG3-
targeted TFs whose expression is enriched in human fetal beta cells,
suggesting that they could play a role in human beta-cell development
(Suppl. Figure 7B). For ISX, but not ETS2, we did validate the capacity
of NEUROG3 to activate transcription via this region (Suppl. Figure 5).
Regarding alpha destiny, no peaks were assigned to ARX, which is
essential for alpha cell development in the mouse and human [52,55].
Of note, we found NEUROG3 binding regions associated with IRX1 and
IRX2, which are both enriched in human fetal (Figure 5A) and adultMOLECULAR METABOLISM 53 (2021) 101313  2021 The Authors. Published by Elsevier GmbH. This is an open a
www.molecularmetabolism.com(Figure 5C and [30,56]) alpha cells, as well as in the in vitroederived
NEUROG3-Venusþ PEP cells (Figure 4A). Interestingly, Irx2 was
induced by ectopic Neurog3 expression in the chick endoderm [11] and
downregulated in hPSC-derived human islet cells lacking ARX [55].
Thus, IRX1/2 are attractive, alpha-specific, NEUROG3 direct targets,
although their function in alpha cell development remains to be
studied.
Compared to alpha and beta cells, less is known regarding the
regulation of delta cell destiny. We did not find any binding of NEUROG3
associated with the delta transcription factor HHEX [57]. Nevertheless,
our analysis pointed to possible NEUROG3-dependent candidate reg-
ulators of delta cell development. Indeed, we identified a NEUROG3
binding site within the first intron of the EGFR family member Erb-B2ccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 11
Figure 7: T2D and fasting glycemia (FG)-associated genetic variants located within NEUROG3-bound regions. (A) Venn diagram illustrating the overlap of NEUROG3-bound
regions and the 23,154 T2D-FG SNPs distributed over 109 risk loci compiled by Miguel-Escalada et al. [32]. (B) The 8 SNPs within NEUROG3-bound regions, in the indicated 4 risk
loci, and their nearest genes. (CeD) NEUROG3 binding to the GIPR-SNRPD2-FBXO46-SIX5 (C) and UBE2Z-TTLL6 (D) loci. See Figure 2E for legend description.
Original ArticleReceptor Tyrosine Kinase 4 (ERBB4) gene (Suppl. Figure 7C) that is
highly and specifically expressed in human fetal (Suppl. Figure 7A) and
adult [56] delta cells and whose ligand neuregulin-4 (NGR-4) was
found to be essential for the determination of delta cells in mice [58].
Of note, ERBB4 is cleaved by gamma-secretase to generate an
intracellular domain endowed with TF regulatory activity [59].
Furthermore, during human in vitro beta cell differentiation, a gamma
secretase inhibitor is added at the endocrine progenitor stage to inhibit
Notch signaling and promote the beta lineage [41]. Whether the
concomitant inhibition of ERBB4, impeding the delta destiny, could
favor the beta destiny remains to be tested.
Altogether, mapping NEUROG3 occupancy revealed an unexpectedly
broad direct control of TFs in the endocrine gene regulatory network.
3.6. NEUROG3 binds to genes involved in islet cell function
As mentioned above, gene ontology analyses revealed that many
NEUROG3-bound genes were associated with insulin secretion,
suggesting that NEUROG3 could regulate the expression of genes of
the hormone secretory machinery. Indeed, NEUROG3 bound to genes
linking glucose metabolism to electrical activity in beta cells and
subsequent insulin secretion [60], such as the glucose sensor GCK12 MOLECULAR METABOLISM 53 (2021) 101313  2021 The Authors. Published by Elsevier GmbH. Tand the subunits of the ATP-sensitive Kþ channel, ABCC8 or KCNJ11
(Figure 6AeC). Interestingly, other Kþ (ATP-independent) channel
genes (e.g., KCNA3, KCNB2, KCND3, KCNK16, KCNMA1), which also
contribute to glucose-stimulated insulin secretion and are expressed
in human fetal islet cells [38], were bound by NEUROG3 (Figure 6A
and Suppl. Table 3). In the same line, the voltage-dependent Ca2þ
channels (e.g., CACNA1A, CACNA1C, CACNA1E, CACNA2D1,
CACNB2) or genes involved in the formation, composition, or release
of secretory granules (e.g., CHGA, SCG2, SLC30A8/ZNT8, SLC18A2/
VMAT2, RGS16, RGS4, SYT7, SYT13 SYT3, STX2, STXBP1) or pro-
insulin processing (e.g., PCSK1, CPE) (Figure 6A, Suppl. Figure 8A, B
and Suppl. Table 3) were associated with NEUROG3 binding sites. We
did not find any binding of NEUROG3 to hormone genes. NEUROG3
binding was also identified in the somatostatin receptor genes
SSTR1, SSTR2, and SSTR5, involved in the paracrine regulation of
insulin and glucagon secretion [60] (Suppl. Figure 8C, and
Suppl. Table 3).
These findings regarding NEUROG3-bound gene involvement in islet
cell function were unexpected due to the transient expression of
NEUROG3 in endocrine progenitors. Interestingly, several of these
target genes, including ABCC8/KCNJ11, CACNA1A, SLC30A8, andhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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SLC18A2, are weakly or not expressed in endocrine progenitors
compared to more-differentiated hESC-derived beta (SC-beta) or adult
islet cells (Figure 6C, D and Suppl. Figure 8A, [30]). We noticed that
some of these genes (e.g., ABCC8 or KCNJ11, and SLC18A2)
(Figure 6C and Suppl. Figure 8) are marked by H3K27me3 at or near
their TSS, suggesting that NEUROG3 could prime these genes at the
endocrine progenitor stage, but subsequent binding by other TFs could
be required for their full activation. Thus, NEUROG3 might not only
promote islet destiny in uncommitted pancreatic progenitors, but also
control the initiation of later generic endocrine programs in maturing
islet and beta cells.
3.7. NEUROG3 binding at T2DM risk variants
Genome-wide association studies (GWAS) have identified hundreds of
genetic variants associated with increased T2DM susceptibility [61]. It
is essential to understand how these T2DM-linked SNPs contribute to
the disease, which genes they affect and how, and whether it is by
altering the protein sequence or, most frequently, distal cis-regulatory
elements. Miguel-Escalada et al. [32] have compiled a list of 23,154
genetic variants associated with T2D and/or fasting glycemia (T2D/FG
SNPs) within 109 loci. When comparing the disease-associated vari-
ants with NEUROG3-bound sites, we found eight SNPs within five
NEUROG3 binding sites (P ¼ 1.5e-3), falling within four T2D/FG loci
(Figure 7A, B and Suppl. Table 10). All eight risk alleles lie within
NEUROG3-binding sites at a promoter region: rs1799884 for GCK;
rs114152784 for MDC1; rs635299, rs113815244, and rs7245708 for
SIX5, AX746967 and QPCTL and/or SNRPD2 at the GIPR locus,
respectively; and rs200168742, rs35130875, and rs1962412 for
ATP5G1 and/or HI-LNC4227 at the UBE2Z locus (Figures 6B and 7Ce
D). None of the eight SNPs overlap with a NEUROG3-binding motif;
however, they still may alter NEUROG3 binding indirectly, and thus also
affect the expression of NEUROG3 target genes. Similarly, SNPs
located not directly within the NEUROG3 binding site, but in the
NEUROG3-bound enhancer, may influence NEUROG3 binding on its
sites. By intersecting the T2D/FG SNPs [32] with PEP enhancers, we
found 1,445 SNPs (P ¼ 3.05e-215) coinciding with a PEP enhancer
[30], with 152 SNPs (P ¼ 2.95e-27) within an enhancer bound by
NEUROG3 (Suppl. Table 10). Thus, T2D/FG SNPs are enriched in PEP
enhancers bound by NEUROG3, suggesting that these mutations may
alter the expression of genes co-regulated by NEUROG3.
4. CONCLUSION
Despite the major progress in generating functional beta cells from
pluripotent stem cells for cell therapy in diabetes, directed differenti-
ation protocols lack robustness, and obtaining glucose-responsive
cells remains difficult. The overall strategy was to mimic pancreas
and islet developmental programs identified mainly in rodents. While
the successful production of insulin-producing cells from PSC in vitro
attests that these programs are remarkably conserved, it is important
to acquire additional insights into the gene regulatory networks con-
trolling islet cell development in humans to optimize differentiation
protocols. Notwithstanding the essential function of NEUROG3 in islet
cell development in mice and humans, its downstream direct targets
that implement the endocrinogenic program are essentially unknown.
Identifying NEUROG3 binding sites in purified hiPSC-derived PEP, using
the CUT&RUN technique, revealed over 1000 novel putative direct
targets. Importantly, NEUROG3 binding largely overlaps with PEP active
enhancers (H3K27ac binding) as defined by others [30], underlining
the importance of NEUROG3 in promoting gene expression in PEPs. Our
study revealed that NEUROG3 binds to a high number of important isletMOLECULAR METABOLISM 53 (2021) 101313  2021 The Authors. Published by Elsevier GmbH. This is an open a
www.molecularmetabolism.comTF genes and novel possible transcriptional regulators of islet cell
differentiation. Moreover, a plethora of genes involved at several key
steps of the insulin secretion pathway are bound by NEUROG3. Finally,
we revealed that NEUROG3 binding regions overlap with a series of
T2DM-associated SNPs. Altogether, our results suggest that NEUROG3
controls the progression of islet cell differentiation and the setup of
hormone secretory machinery. The pleiotropic functions of NEUROG3
direct targets support the severity of NEUROG3 mutations in mice and
humans and the potential of NEUROG3 to induce an endocrinogenic
program when expressed ectopically. To our knowledge, this is the
first genome-wide characterization of NEUROG3 occupancy in hiPSC-
derived PEPs.
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